Hodgkin's disease
Not recruitingStudy of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission
Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission
- Disease:Hodgkin's disease
- Substances:CisplatinGemcitabine+2
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Cisplatin
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting




